The Journal of nutritionJun 20, 2026

Preventing Malnutrition While Using GLP-1 Medications: New Findings and Opportunities for Coordinated Nutrition Care

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 22, 2026

Abstract

GLP-1-based therapies are associated with significant weight loss and metabolic improvements but may leave patients without necessary nutritional support.

Many patients on GLP-1 therapy drastically reduce energy intake, risking inadequate protein and micronutrient levels.
Consequences of insufficient dietary guidance may include low fiber intake and loss of lean muscle mass.
Clinical practice often lacks integrated nutritional assessment, despite its importance recognized by obesity societies.
Registered dietitians and behavioral health professionals could play a crucial role in maintaining nutrient adequacy and reducing side effects.
Key research priorities include developing nutritional screening tools and defining evidence-based nutrient targets for at-risk patients.

Simplified

Glucagon-like peptide-1 (GLP-1)-based therapies have transformed obesity treatment, resulting in significant weight loss and broad metabolic improvements. However, their rapid adoption has outpaced the development of adequate nutritional support systems, leaving many patients without dietary guidance despite experiencing profound reductions in appetite and food intake. People often drastically cut their energy consumption, risking inadequate protein intake, micronutrient deficiencies, low fiber intake, and loss of lean mass, consequences that are largely preventable with proper guidance. Yet, in clinical practice, integrated nutritional assessment is rarely provided, despite obesity societies recognizing its importance. This perspective synthesizes emerging evidence on the nutritional risks associated with GLP-1-based therapy, examines the gap between guideline recommendations and real-world practice, and argues that integrated nutritional care must become a core (not optional) part of GLP-1-based obesity treatment. We emphasize the role of registered dietitians and behavioral health professionals in maintaining nutrient adequacy, reducing gastrointestinal side effects, and preserving lean mass. Additionally, we identify key research priorities: developing validated nutritional screening tools, defining evidence-based nutrient targets, characterizing high-risk patient profiles, and researching the long-term outcomes of integrated nutrition and pharmacotherapy. As GLP-1 prescriptions reach millions of patients across diverse and often under-resourced clinical settings, integrating nutrition into this care model is not just advisable; it is urgent.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Conflict of interest The authors report no conflicts of interest.

PubMed

Preventing Malnutrition While Using GLP-1 Medications: New Findings and Opportunities for Coordinated Nutrition Care

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief